Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marco Oltrecolli"'
Autor:
Eleonora Cabitza, Marta Pirola, Cinzia Baldessari, Giuditta Bernardelli, Elena Zunarelli, Stefania Pipitone, Maria Giuseppa Vitale, Cecilia Nasso, Eleonora Molinaro, Marco Oltrecolli, Elisa D’Agostino, Vincenzo Dario Mandato, Andrea Palicelli, Massimo Dominici, Roberto Sabbatini
Publikováno v:
Journal of Medical Case Reports, Vol 17, Iss 1, Pp 1-5 (2023)
Abstract Background Ovarian cancer is metastatic at presentation in about 62% of cases, but brain metastases are rare, reported in 3.3–4% of patients. Brain metastasis seems to be more frequent in advanced stages at diagnosis and in patients with B
Externí odkaz:
https://doaj.org/article/a4f5a6c85c3d401a928fbbcb6aa4d4bf
Autor:
Claudia Piombino, Stefania Pipitone, Elena Tonni, Luciana Mastrodomenico, Marco Oltrecolli, Cyrielle Tchawa, Rossana Matranga, Sara Roccabruna, Elisa D’Agostino, Marta Pirola, Francesca Bacchelli, Cinzia Baldessari, Maria Cristina Baschieri, Massimo Dominici, Roberto Sabbatini, Maria Giuseppa Vitale
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 9, p 4624 (2024)
More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatme
Externí odkaz:
https://doaj.org/article/eaeacfb0992c4dc6b00b1ed357bf4eb5
Autor:
Claudia Piombino, Marco Oltrecolli, Elena Tonni, Marta Pirola, Rossana Matranga, Cinza Baldessari, Stefania Pipitone, Massimo Dominici, Roberto Sabbatini, Maria Giuseppa Vitale
Publikováno v:
Cancers, Vol 15, Iss 20, p 4945 (2023)
De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction
Externí odkaz:
https://doaj.org/article/b249130b8e9d487eb8b94a12d82c66a9
Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers
Autor:
Ilenia Mastrolia, Virginia Catani, Marco Oltrecolli, Stefania Pipitone, Maria Giuseppa Vitale, Valentina Masciale, Chiara Chiavelli, Carlo Augusto Bortolotti, Cecilia Nasso, Giulia Grisendi, Roberto Sabbatini, Massimo Dominici
Publikováno v:
Biology, Vol 12, Iss 6, p 877 (2023)
Renal cell carcinoma (RCC) is the second most common cancer of the urinary system. The current therapeutic strategies are based on partial or total nephrectomy and/or targeted therapies based on immune checkpoint inhibitors to which patients are ofte
Externí odkaz:
https://doaj.org/article/cee52440245645c9808ead623d8c9f55
Autor:
Cinzia Baldessari, Stefania Pipitone, Eleonora Molinaro, Krisida Cerma, Martina Fanelli, Cecilia Nasso, Marco Oltrecolli, Marta Pirola, Elisa D’Agostino, Giuseppe Pugliese, Sara Cerri, Maria Giuseppa Vitale, Bruno Madeo, Massimo Dominici, Roberto Sabbatini
Publikováno v:
Cancers, Vol 15, Iss 5, p 1518 (2023)
Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. B
Externí odkaz:
https://doaj.org/article/b6d2b0afbcd14df08052f507cba4df04
Autor:
Ilenia Mastrolia, Virginia Catani, Marco Oltrecolli, Stefania Pipitone, Maria Giuseppa Vitale, Valentina Masciale, Chiara Chiavelli, Carlo Augusto Bortolotti, Cecilia Nasso, Giulia Grisendi, Roberto Sabbatini, Massimo Dominici
Renal cell carcinoma (RCC) is the second most common cancer of the urinary system. The current therapeutic strategies are based on partial or total nephrectomy and/or targeted therapies based on immune checkpoint inhibitors to which patients are ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a0072e9f2fe0de252f1ed003db7a156
https://doi.org/10.20944/preprints202304.1185.v1
https://doi.org/10.20944/preprints202304.1185.v1
Autor:
Maria Giuseppa Vitale, Massimo Dominici, Cinzia Baldessari, Martina Fanelli, Roberto Sabbatini, Marco Oltrecolli, Cecilia Nasso
Publikováno v:
Expert review of anticancer therapy. 21(11)
Introduction In the last decade, there have been substantial changes in the management of metastatic renal cell carcinoma (mRCC) with combined regimens with immune checkpoint inhibitors (ICI) replacing targeted therapies. These combined regimens incl